Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Ä¡·á ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Idiopathic Pulmonary Fibrosis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
»óǰÄÚµå : 1573880
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 268 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Ä¡·á ½ÃÀåÀº 2023³â 30¾ï ´Þ·¯ ±Ô¸ð·Î 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 6.9% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ ¼ºÀåÀÇ ¿øµ¿·ÂÀº Àα¸ °í·ÉÈ­¿Í ȯ°æÀû ¿äÀΰú °ü·ÃµÈ Ư¹ß¼º Æó¼¶À¯Áõ(IPF)ÀÇ ¹ßº´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ÇÔ²² IPFÀÇ È®»êÀº Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡ µµÀüÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø ÀÚ·á¿¡ µû¸£¸é, IPF´Â ³²¼º¿¡°Ô ¸¹ÀÌ ¹ß»ýÇϸç, ºÏ¹ÌÀÇ À¯º´·üÀº 1¸¸ ¸í´ç 2.40-2.98¸íÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº À¯º´·üÀº Ç¥Àû Ä¡·á¿Í ¸é¿ª¿ä¹ýÀ» Æ÷ÇÔÇÑ Ä¡·á Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ȯÀÚÀÇ Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷°í ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

IPF¸¦ Àû½Ã¿¡ ¹ß°ßÇÏ°í °ü¸®Çϱâ À§Çؼ­´Â Áø´Ü ±â¼úÀÇ ¹ßÀüÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÷´Ü ¿µ»ó Áø´Ü ½Ã½ºÅÛ°ú ºñħ½ÀÀû µµ±¸¸¦ ÅëÇØ ÀÇ·á Àü¹®°¡µéÀº IPF¸¦ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¶±â ¹ß°ßÀº Àû½Ã¿¡ °³ÀÔÇÏ¿© ȯÀÚ °á°ú¸¦ °³¼±ÇÏ°í ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.

2023³â, ¾àǰ Á¾·ùº° ½ÃÀå ±Ô¸ð´Â 18¾ï ´Þ·¯·Î Æò°¡µÇ¾î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. NIH µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¸Å³â ¾à 10¸¸ ¸íÀÌ IPF Áø´ÜÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÎÁöµµ Çâ»ó, Àû½Ã Áø´Ü ¹× ¾à¹° È¿°úÀÇ °³¼±¿¡ ±âÀÎÇÕ´Ï´Ù. ¾à¹° Á¾·ù·Î´Â Ç×¼¶À¯È­Á¦, Ç׿°ÁõÁ¦, ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å, ¸é¿ª¾ïÁ¦Á¦, ±âŸ µîÀÌ ÀÖ½À´Ï´Ù. ÇǸ£Æä´Ïµ·À̳ª ´ÑÅ×´Ù´Õ°ú °°Àº Ç×¼¶À¯È­Á¦´Â Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß´Â È¿°ú°¡ ÀÖ¾î ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù. ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å´Â È¿°ú°¡ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ ¼±È£µµ°¡ ¶³¾îÁö°í ÀÖÀ¸¸ç, ¾ÆÀÚÆ¼¿ÀÇÁ¸°À̳ª ¹ÌÄÚÆä³î»ê ¸ðÆäÆ¿°ú °°Àº ¸é¿ª¾ïÁ¦Á¦´Â ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å¿Í º´ÇàÇÏ¿© ÀϺΠ°æ¿ì¿¡¸¸ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù.

2023³â¿¡´Â 50¼¼ À̻󿡼­ ´õ ³ôÀº À¯º´·üÀ» º¸À̱⠶§¹®¿¡ ¼ºÀÎ ºÎ¹®ÀÌ 20¾ï ´Þ·¯ ±Ô¸ð·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ¿¬·ÉÀÌ IPF ¹ßº´ÀÇ Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ ³ë³âÃþÀÌ Ä¡·áÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀº Àü ¼¼°è °í·ÉÈ­ Ãß¼¼¿Í ÀÎÁö ¹× Áø´ÜÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ´õ¿í ÃËÁøµÇ°í ÀÖÀ¸¸ç, NIH µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 10¸¸ ¸íÀÌ IPF¸¦ ¾Î°í ÀÖÀ¸¸ç, ´ëºÎºÐ 65¼¼ ÀÌ»óÀÇ ¼ºÀÎÀÔ´Ï´Ù.

ºÏ¹Ì Ư¹ß¼º Æó¼¶À¯Áõ(IPF) Ä¡·á ½ÃÀåÀº 2032³â±îÁö 25¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 6.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­ ¹Ì±¹ÀÌ ¾ÐµµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ IPF À¯º´·ü Áõ°¡ ¿äÀÎÀ¸·Î´Â Àα¸ °í·ÉÈ­, À¯ÀüÀû ¿äÀÎ, ȯ°æÀû ¿µÇâ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ÀÇ·á ÀÎÇÁ¶ó¿Í °­·ÂÇÑ R&D ¿ª·®Àº IPF Ä¡·áÀÇ Àü¸ÁÀ» Å©°Ô Á¿ìÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦¾à»ç, ¿¬±¸±â°ü, ÀÇ·áÁøÀÇ °­·ÂÇÑ Çù·ÂÀº ±â¼ú Çõ½ÅÀ» ÃËÁøÇϰí È¿°úÀûÀÎ Ä¡·á¹ýÀ» ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖÀ¸¸ç, IPF¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °í·ÉÃþ¿¡¼­ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï »óȲ

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿¬·ÉÃþº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Idiopathic Pulmonary Fibrosis Treatment Market was valued at USD 3 billion in 2023 and is projected to expand at a CAGR of 6.9% from 2024 to 2032. This growth is driven by the rising incidence of idiopathic pulmonary fibrosis (IPF), linked to aging populations and environmental factors.

As the global population ages, the prevalence of IPF challenges healthcare systems worldwide. Data from the National Institutes of Health shows IPF is more common in men, with North American rates ranging from 2.40 to 2.98 cases per 10,000 individuals. This prevalence has spurred innovations in treatment, including targeted therapies and immunotherapies, broadening patient care options and fueling market expansion.

Advances in diagnostic technologies have been crucial for the timely detection and management of IPF. Advanced imaging systems and non-invasive tools enable healthcare professionals to identify IPF earlier. Early detection allows for timely interventions, enhancing patient outcomes and driving market growth.

The overall idiopathic pulmonary fibrosis treatment industry is classified based on treatment type, route of administration, age group, end-use, and region.

In 2023, the drug class segment led the market with a valuation of USD 1.8 billion. This growth is due to increased awareness, timely diagnoses, and improved drug efficacy. NIH data indicates that around 100,000 individuals in the U.S. are diagnosed with IPF annually. The drug class segment includes antifibrotic drugs, anti-inflammatory drugs, corticosteroids, immunosuppressants, and others. Antifibrotic drugs like pirfenidone and nintedanib dominate due to their ability to slow disease progression. Corticosteroids have declined in preference due to limited effectiveness, while immunosuppressants such as azathioprine and mycophenolate mofetil are used in select cases, often alongside corticosteroids.

In 2023, the adult segment led the market with a valuation of USD 2 billion due to the disease's higher prevalence in those aged 50 and above. With age being a significant factor in IPF incidence, older adults are the primary focus for treatment. This segment's growth is further bolstered by the global aging trend and advancements in awareness and diagnostics. NIH data notes that while 100,000 people in the U.S. are affected by IPF, a significant majority are adults over 65.

North America idiopathic pulmonary fibrosis treatment market is set to reach USD 2.5 billion by 2032, with a projected CAGR of 6.8% over the forecast period. The U.S. commands a dominant position in this market. Factors contributing to the rising IPF prevalence in the U.S. include an aging demographic, genetic factors, and environmental influences. The region's advanced medical infrastructure and strong R&D capabilities significantly shape the IPF treatment landscape. Moreover, robust collaborations among pharmaceutical firms, research entities, and healthcare professionals drive innovation and ensure effective treatment availability. As awareness grows and the disease's incidence rises among older demographics, the market is poised for continued expansion.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â